Immunome, Inc. focuses on developing antibody therapeutics for oncology and infectious disease. Their lead oncology program has a tumor-derived immune checkpoint targeting mechanism, while their antibody cocktail product aims to treat COVID-19. The biopharmaceutical company was established in 2006 and is headquartered in Exton, Pennsylvania.